UF010 (UF-010; UF 010) is a novel, potent and selective class I HDAC inhibitor with potential anticancer activities. HDAC isoforms (HDAC1, HDAC2, HDAC3, HDAC8, HDAC6, and HDAC10) are inhibited with IC50 values of 0.5 nM, 0.1 nM, 0.06 nM, 1.5 nM, 9.1 nM, and 15.3 nM, in that order. The use of histone deacetylase inhibitors (HDACi) as clinical anticancer therapies has great therapeutic promise. Yet, the HDACi that are currently on the market have unfavorable pharmacological characteristics, poor isoform selectivity, and off-target activity. For HDACi to get around these restrictions, new chemotypes are required. UF010 is a competitive inhibitor that binds to HDAC in a fast-on, slow-off manner. UF010 inhibits class I HDAC to prevent the growth of cancer cells. Global alterations in gene expression and protein acetylation result from this, which simultaneously inhibits multiple oncogenic pathways and activates tumor suppressor pathways. The UF010 class of compounds is supported in its preclinical development for potential therapeutic applications by its isotype selectivity and intriguing biological activities in suppressing tumor cell proliferation.

Physicochemical Properties

Molecular Formula	C11H15BRN2O
Molecular Weight	271.16
Exact Mass	270.036
Elemental Analysis	C, 48.72; H, 5.58; Br, 29.47; N, 10.33; O, 5.90
CAS #	537672-41-6
Related CAS #	537672-41-6
PubChem CID	4596836
Appearance	White to off-white crystalline solid
Density	1.3±0.1 g/cm3
Boiling Point	326.7±34.0 °C at 760 mmHg
Flash Point	151.4±25.7 °C
Vapour Pressure	0.0±0.7 mmHg at 25°C
Index of Refraction	1.550
LogP	3.46
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	2
Rotatable Bond Count	5
Heavy Atom Count	15
Complexity	191
Defined Atom Stereocenter Count	0
SMILES	BrC1C([H])=C([H])C(=C([H])C=1[H])C(N([H])N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O
InChi Key	BVQCFCYPFJOOAV-UHFFFAOYSA-N
InChi Code	InChI=1S/C11H15BrN2O/c1-2-3-8-13-14-11(15)9-4-6-10(12)7-5-9/h4-7,13H,2-3,8H2,1H3,(H,14,15)
Chemical Name	4-bromo-N'-butylbenzohydrazide
Synonyms	UF010; UF 010; UF-010
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	HDAC3 (IC50 = 0.06 μM); HDAC2 (IC50 = 0.1 μM); HDAC1 (IC50 = 0.5 μM); HDAC8 (IC50 = 9.1 μM); HDAC10 (IC50 = 15.3 μM); HDAC11 (IC50 = 44.5 μM)
ln Vitro	UF010 primarily inhibits the G1/S transition with an increased G1 cell population and a decreased cell population in the S phase in a dose-dependent manner in cell-cycle analysis using MDA-MB-231 cells. In cell culture medium containing 10% fetal bovine serum, UF010 has a half-life of 15.8 hours[1].
Cell Assay	For six hours, HCT116 and A549 cells are exposed to either DMSO or etoposide (10 μM). One hour prior to cell lysis, TSA (0.2 μM), MS-275, and UF010 (2 μM) are added. Western blotting is performed on the whole cell lysates using antibodies to the specified proteins. It is found that PCNA is a loading control.
References	[1]. Chem Biol . 2015 Feb 19;22(2):273-84.

Solubility Data

Solubility (In Vitro)

DMSO: ≥ 50mg/mL Water: < 1mg/mL Ethanol: N/A

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (9.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (9.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.6879 mL	18.4393 mL	36.8786 mL
	5 mM	0.7376 mL	3.6879 mL	7.3757 mL
	10 mM	0.3688 mL	1.8439 mL	3.6879 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.